AT1-RAngiotensin II type 1-Receptor
AT1-RAngiotensin II Type 1-Receptors
References in periodicals archive ?
The Company's scientists found that upregulation of AT1-R is present in IDC patients who are ER+ and that ER+ IDC tumor cells responded to pharmacologic intervention with AT1-R antagonists.
Dimmler also presented preclinical data showing that the activity of an AT1-R antagonist (candesartan, a hypertension drug) is similar to that of tamoxifen, a selective estrogen receptor modulator used in treating breast cancer for decades.
Additionally, our AT1-R findings represent an opportunity to extend the use and patent life of existing therapies while offering significant benefit to a large number of breast cancer patients.